Related Experiment Videos
RHC 80267 does not inhibit the diglyceride lipase pathway in intact platelets
Biochemical and Biophysical Research Communications
|October 14, 1983
Summary
The drug RHC 80267 inhibits diglyceride and monoglyceride lipase activities in platelet microsomes. However, it is ineffective in intact platelets, limiting its use for studying the diglyceride lipase pathway.
Area of Science:
- Biochemistry
- Pharmacology
- Platelet Physiology
Background:
- Diglyceride lipase pathway is involved in platelet activation.
- RHC 80267 is a known inhibitor of diglyceride lipase.
- Previous studies suggest RHC 80267's efficacy in intact human platelets.
Purpose of the Study:
- To investigate the efficacy of RHC 80267 on diglyceride and monoglyceride lipase activities in platelet microsomes and intact platelets.
- To evaluate the utility of RHC 80267 in studying the diglyceride lipase pathway in vivo.
Main Methods:
- Enzyme activity assays on platelet microsomes.
- Stimulation of intact platelets with thrombin.
- Measurement of diglyceride and monoglyceride accumulation.
- Assessment of arachidonate release.
Main Results:
- RHC 80267 inhibited diglyceride lipase (IC50 = 15 microM) and monoglyceride lipase (IC50 = 11 microM) in platelet microsomes.
- The drug was ineffective in intact platelets.
- 1,2-diglyceride and 2-monoglyceride accumulated in thrombin-stimulated intact platelets treated with RHC 80267.
- Arachidonate release remained unimpaired in intact platelets.
Conclusions:
- RHC 80267 is not suitable for evaluating the diglyceride lipase pathway in intact platelets.
- The drug's inhibitory effects are limited to cell-free systems.
- Further research is needed to understand RHC 80267's mechanism in intact cells.